Nelarabine After Induction Fails to Improve Event-Free Survival in Adult T-ALL
Rowntree et alHemaSphere

In the phase 3 UKALL14 randomized controlled trial (NCT01085617), investigators evaluated whether incorporating a single cycle of nelarabine following second induction therapy improves clinical outcomes in adults aged 25 to 65 years with T-cell precursor acute lymphoblastic leukemia (T-ALL). Between 2011 and 2018, 143 patients were randomized to receive standard of care (SOC; n = 75) or SOC plus nelarabine at 1.5 g/m² administered on days 1, 3, and 5 (n = 68). The primary endpoint of event-free survival (EFS) was not significantly improved with the addition of nelarabine, demonstrating an EFS of 62.7% in the nelarabine arm versus 58.2% in the SOC arm (hazard ratio [HR] 0.86; 95% CI, 0.52–1.43; P = 0.57).
Safety evaluations confirmed that nelarabine was tolerable in this setting. There were no statistically significant differences between treatment arms in rates of severe adverse events or nonrelapse mortality. Importantly, the incidence of grade 3 to 4 neurotoxicity did not differ between the two arms. The 3-year cumulative incidence of relapse was comparable at 28.9% with nelarabine versus 31.0% with SOC. Overall, relapses occurred rapidly, with 90.9% (40 of 44) arising within 2 years of randomization; post-relapse prognosis remained poor, with a median overall survival of 5.7 months irrespective of treatment arm.
Diagnostic characterization of samples provided insights into leukemia biology and risk stratification. Analysis of the T-cell receptor gamma (TCRg) locus revealed a trend toward higher relapse rates in immature cases characterized by the absence of biallelic TCRg deletion (ABD) compared to patients without ABD (37.3% vs 19.5%; P = 0.066). Targeted sequencing of 133 diagnostic samples across NOTCH1, FBXW7, NRAS, KRAS, and PTEN showed no differences in complete response (CR) or survival based on NOTCH1 or FBXW7 mutation status. However, patients with NRAS mutations (n = 12) had significantly worse CR rates and EFS relative to wild-type cases, highlighting a distinct molecular subgroup associated with poor prognosis.
Key Takeaways
- Post-induction consolidation with one cycle of nelarabine did not significantly improve event-free survival compared to standard of care alone (62.7% vs 58.2%; HR 0.86, 95% CI 0.52–1.43; P = 0.57) or reduce 3-year cumulative relapse rates (28.9% vs 31.0%).
- Nelarabine was well tolerated with no observed increases in nonrelapse mortality, severe adverse events, or grade 3–4 neurotoxicity compared to standard therapy.
- Among 133 patients evaluated for molecular alterations, those with NRAS mutations (n = 12) experienced significantly inferior complete response rates and event-free survival compared to NRAS wild-type counterparts.
Read the original sourceHemaSphere
